What happened
The FDA Pharmacy Compounding Advisory Committee, PCAC, met on July 23 and 24, 2026 to review seven peptides nominated for inclusion on the 503A bulk drug substances list. Inclusion on that list is what allows a compounding pharmacy to legally prepare a substance for an individual patient under a prescription. Exclusion means the substance is not available through the regulated pharmacy channel.
The panel voted in favor of six of the seven: BPC-157, MOTS-c, KPV, TB-500, Epitalon, and Semax. Only DSIP (also known as Emideltide) was voted down, on the basis of safety data gaps and purity concerns. This is the first time a major FDA advisory panel has recommended broad legalization of research-chemical peptides through the compounding channel.
The vote went against the recommendation of FDA's own internal reviewers on every single peptide that passed.
Why the vote is not the finish line
PCAC recommendations are advisory. They inform the FDA's formal rule-making process, but they do not bind the agency. The FDA's own review scientists recommended against all seven peptides in their published materials for the meeting, citing insufficient safety data, unclear manufacturing controls, and inadequate evidence of clinical benefit. The FDA can accept PCAC's recommendation, reject it, or add restrictions.
The formal rule-making process from a PCAC recommendation to a final rule on the 503A list typically takes 12 to 24 months. During that window, none of these peptides is legally compoundable. Any current sales in the US are still research-chemical sales or, in some cases, non-compliant compounding.
What each peptide is
What FDA reviewers actually said
The FDA's own briefing documents, published ahead of the meeting, made a consistent set of arguments against each nomination. Safety data was largely animal-only or from small unblinded human series. Manufacturing controls were considered inadequate to guarantee purity and identity of what compounding pharmacies would actually be preparing. Clinical benefit was not clearly demonstrated in placebo-controlled trials for any of the seven nominations.
That the panel voted the other way is unusual, but not unprecedented. PCAC has, in past meetings, disagreed with FDA staff on specific nominations. What is unusual here is that it happened across six peptides in a single session.
What changes for buyers
Nothing changes in the near term. These peptides remain research chemicals in the US. Compounding pharmacies cannot prepare them for prescription use unless and until the FDA finalizes a rule that adds them to the 503A list. If that rule arrives, buyers in the US would have a legal, quality-controlled pharmacy channel for these substances. If the FDA rejects PCAC's recommendation, the status quo continues: research-chemical suppliers with variable purity, no pharmacy oversight, and no prescription pathway.
What to watch
- FDA Federal Register notice responding to the PCAC recommendation, expected within 6 to 12 months.
- Public comment period if the FDA proposes to add any of the six to the 503A list, typically 60 to 90 days.
- Independent human trial data on any of the six, which remains the missing piece the FDA reviewers actually asked for.